Zoetis (NYSE:ZTS) Stock Bought by Rep. Gilbert Ray Cisneros, Jr.

by · The Markets Daily

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Zoetis Inc. (NYSE:ZTS). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Zoetis stock on September 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

  • Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
  • Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
  • Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
  • Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
  • Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
  • Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
  • Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
  • Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
  • Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
  • Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.

Zoetis Price Performance

Shares of Zoetis stock traded up $0.57 during midday trading on Wednesday, hitting $74.87. 419,850 shares of the company traded hands, compared to its average volume of 5,519,805. The stock has a market cap of $30.94 billion, a price-to-earnings ratio of 12.34, a PEG ratio of 1.76 and a beta of 0.74. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The firm’s fifty day moving average price is $73.85 and its 200-day moving average price is $84.06. Zoetis Inc. has a 12 month low of $68.77 and a 12 month high of $148.30.

Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm’s quarterly revenue was down .2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.20 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. Zoetis’s dividend payout ratio is 34.93%.

Institutional Trading of Zoetis

Institutional investors have recently modified their holdings of the business. Physician Wealth Advisors Inc. raised its position in Zoetis by 17.4% during the 1st quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock worth $73,000 after buying an additional 91 shares during the last quarter. Brown Lisle Cummings Inc. boosted its stake in shares of Zoetis by 6.3% during the 1st quarter. Brown Lisle Cummings Inc. now owns 1,621 shares of the company’s stock worth $192,000 after acquiring an additional 96 shares in the last quarter. Lipe & Dalton grew its stake in Zoetis by 2.2% in the 1st quarter. Lipe & Dalton now owns 4,698 shares of the company’s stock valued at $555,000 after acquiring an additional 102 shares during the period. Root Financial Partners LLC increased its stake in shares of Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares in the last quarter. Finally, Rexford Capital Inc. raised its holdings in shares of Zoetis by 5.3% during the first quarter. Rexford Capital Inc. now owns 2,352 shares of the company’s stock valued at $278,000 after acquiring an additional 118 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ZTS shares. Piper Sandler dropped their price target on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. Stifel Nicolaus reduced their price objective on Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a research report on Thursday, August 20th. Morgan Stanley set a $85.00 target price on Zoetis in a report on Friday, August 7th. Citigroup dropped their target price on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Finally, UBS Group dropped their target price on Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a research report on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $101.08.

Read Our Latest Stock Report on ZTS

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Zoetis Company Profile

(Get Free Report)

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.

The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.

Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health.

See Also